Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease by Astarita, Giuseppe et al.
Deficient Liver Biosynthesis of Docosahexaenoic Acid
Correlates with Cognitive Impairment in Alzheimer’s
Disease
Giuseppe Astarita
1,2, Kwang-Mook Jung
1, Nicole C. Berchtold
3, Vinh Q. Nguyen
4, Daniel L. Gillen
4,
Elizabeth Head
5, Carl W. Cotman
3, Daniele Piomelli
1,6,7*
1Department of Pharmacology, University of California Irvine, Irvine, California, United States of America, 2Department of Experimental Medicine and Biochemical
Sciences, University of Rome Tor Vergata, Rome, Italy, 3Institute for Brain Aging and Dementia, University of California Irvine, Irvine, California, United States of America,
4Department of Statistics, University of California Irvine, Irvine, California, United States of America, 5Sanders-Brown Center on Aging, University of Kentucky, Lexington,
Kentucky, United States of America, 6Department of Biological Chemistry, University of California Irvine, Irvine, California, United States of America, 7Unit of Drug
Discovery and Development, Italian Institute of Technology, Genoa, Italy
Abstract
Reduced brain levels of docosahexaenoic acid (C22:6n-3), a neurotrophic and neuroprotective fatty acid, may contribute to
cognitive decline in Alzheimer’s disease. Here, we investigated whether the liver enzyme system that provides
docosahexaenoic acid to the brain is dysfunctional in this disease. Docosahexaenoic acid levels were reduced in temporal
cortex, mid-frontal cortex and cerebellum of subjects with Alzheimer’s disease, compared to control subjects (P=0.007).
Mini Mental State Examination (MMSE) scores positively correlated with docosahexaenoic/a-linolenic ratios in temporal
cortex (P=0.005) and mid-frontal cortex (P=0.018), but not cerebellum. Similarly, liver docosahexaenoic acid content was
lower in Alzheimer’s disease patients than control subjects (P=0.011). Liver docosahexaenoic/a-linolenic ratios correlated
positively with MMSE scores (r=0.78; P,0.0001), and negatively with global deterioration scale grades (P=0.013).
Docosahexaenoic acid precursors, including tetracosahexaenoic acid (C24:6n-3), were elevated in liver of Alzheimer’s disease
patients (P=0.041), whereas expression of peroxisomal D-bifunctional protein, which catalyzes the conversion of
tetracosahexaenoic acid into docosahexaenoic acid, was reduced (P=0.048). Other genes involved in docosahexaenoic acid
metabolism were not affected. The results indicate that a deficit in D-bifunctional protein activity impairs docosahexaenoic
acid biosynthesis in liver of Alzheimer’s disease patients, lessening the flux of this neuroprotective fatty acid to the brain.
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Introduction
Alzheimer’s disease is a neurodegenerative disorder character-
ized clinically by progressive cognitive impairment [1]. Age is the
most important factor that predisposes persons to the non-familial
form of the disease, which in 2010 affected over 35 million elderly
adults worldwide [2]. How aging interacts with other risk factors
for Alzheimer’s disease [3] is still unknown. It appears, however,
that certain age-related pathologies that are closely associated with
systemic dysfunctions in lipid metabolism – including obesity and
diabetes – might be involved [1].
The polyunsaturated lipid, docosahexaenoic acid (C22:6n-3), is
an essential component of neuronal membranes [4,5] and a
precursor for potent neuroprotective mediators [6–8]. Mammals
obtain docosahexaenoic acid directly from dietary sources,
especially fish, but can also produce it in liver from n-3 fatty
acid precursors present in plants [9–11]. When the diet does not
provide an adequate supply of these foods, as is often the case in
contemporary populations [12], the liver’s capacity to generate
docosahexaenoic acid may become critical to keep normal the
brain levels of this fatty acid [9,11,13,14].
Figure 1 shows an overview of liver docosahexaenoic acid
biosynthesis. Elongase and desaturase enzymes localized in the
endoplasmic reticulum of the hepatocyte progressively add carbon
units and double bonds to shorter-chain n-3 fatty acids, producing
the very-long-chain tetracosahexaenoic acid (C24:6n-3). This is
transported into peroxisomes and then converted to docosahex-
aenoic acid by the sequential action of acyl-coenzyme A oxidases,
D-bifunctional protein and peroxisomal thiolases [15–18]. Liver-
derived docosahexaenoic acid reaches the brain through the
circulation, probably bound to proteins that are also synthesized
by hepatocytes [9].
Evidence indicates that docosahexaenoic acid serves important
neurotrophic functions during early mammalian development
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genesis, but is still unclear whether it plays protective roles in
adulthood and old age. Several, albeit not all, epidemiological and
clinical studies suggest that higher intake of docosahexaenoic acid
decreases the risk of cognitive decline and dementia in elderly
adults [4]. Animal experiments support this conclusion [20–22]
and further indicate that the fatty acid might exert these effects by
promoting neuronal survival [7,23]. The related question of
whether alterations in brain docosahexaenoic acid levels might
accompany cognitive decline has been addressed using post
mortem brain tissue from Alzheimer’s disease patients and age-
matched control subjects [6,24–30]. Despite some disparities,
these investigations generally support the hypothesis that Alzhei-
mer’s disease may be associated with deficits in brain docosahex-
aenoic acid [31]. In the present study, we reexamined this
possibility and searched for supporting correlative evidence that a
failing in brain docosahexaenoic acid integrity might result from
defective n-3 fatty acid metabolism in liver, as previously suggested
by Scott and Bazan [9].
Results
Docosahexaenoic acid levels in brain
Brain levels of non-esterified (‘free’) docosahexaenoic acid were
measured in extracts of temporal cortex, mid-frontal cortex and
cerebellum from a total of 17 control subjects and 37 Alzheimer’s
disease patients. Table 1 shows estimated mean differences
between the two groups after linear regression adjustment for
age, gender and post mortem interval. There were statistically
detectable differences (P,0.05) in docosahexaenoic acid content in
all regions examined. The pooled adjusted difference between
control subjects and Alzheimer’s disease patients (95% confidence
intervals) was 228.87 nanomoles per gram of tissue (249.81,
27.94; P=0.007).
Since docosahexaenoic acid is stored in membrane phospholip-
ids, Table 1 also shows levels of docosahexaenoic acid-containing 1-
stearoyl, 2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine in
the three brain regions. There were significant differences between
control subjects and Alzheimer’s disease patients in all regions. The
pooled adjusted difference between the two groups was 24.14
(27.20, 21.09; P=0.008).
Levels of four n-3 fatty acids that serve as metabolic precursors
for docosahexaenoic acid – a-linolenic acid (C18:3n-3), eicosa-
pentaenoic acid (C20:5n-3), docosapentaenoic acid (C22:5n-3) and
tetracosahexaenoic acid (C24:6n-3) – were quantified in the same
extracts. There were marginally statistically detectable differences
between control subjects and Alzheimer’s disease patients only for
mid-frontal cortex a-linolenic acid (P=0.045) (Table 2). However,
a significant difference between the two groups was detected when
a-linolenic acid content was pooled across brain regions. No
differences were observed for eicosapentaenoic acid and docosa-
pentaenoic acid. Tetracosahexaenoic acid levels were below the
detection limit of our assay (0.5 picomoles per sample).
Figure S1 shows individual data points for docosahexaenoic
acid and 1-stearoyl, 2-docosahexaenoyl-sn-glycero-3-phosphoetha-
nolamine in temporal cortex from control subjects and Alzhei-
mer’s disease patients. The figure also reports the statistical
correlation between temporal cortex docosahexaenoic/a-linolenic
ratios and most recent MMSE scores (Pearson’s correlation
coefficient=0.44, P=0.005). A comparable correlation was
detected between individual MMSE scores and docosahexae-
noic/a-linolenic ratios in mid-frontal cortex (Pearson’s correlation
coefficient=0.38, P=0.018), but not in cerebellum (Pearson’s
correlation coefficient=0.27, P=0.12).
Previous reports suggested that low brain levels of docosahex-
aenoic acid may be accompanied by decreases in n-6 polyunsat-
urated fatty acids [25,28,32]. Here, no significant differences were
observed in mid-frontal cortex and cerebellum for free linoleic acid
(C18:2n-6), eicosatrienoic acid (C20:3n-6) or arachidonic acid
(C20:4n-6) between control subjects and Alzheimer’s disease
patients (Table S1). A difference was detectable, however, for
arachidonic acid in temporal cortex (P=0.02).
Docosahexaenoic acid levels in liver
The conversion of a-linolenic acid into docosahexaenoic acid
occurs primarily in liver [5,9,13]. To examine whether this
pathway is altered in Alzheimer’s disease, n-3 fatty acids were
quantified in liver samples from a second cohort of 9 control
subjects and 14 Alzheimer’s disease patients. These subjects were
selected from a larger available pool because they were negative
for hepatitis B or hepatitis C antibodies and, at autopsy, revealed
no histological signs of liver disease. A list of medications taken by
the subjects is provided in Table S2. There were statistically
detectable differences between the two groups for docosahexae-
noic acid, eicosapentaenoic acid, docosapentaenoic acid and
tetracosahexaenoic acid (Table 3). Additionally, differences were
observed for the docosahexaenoic acid-containing phospho-
lipid, 1-O-19-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-
phosphoethanolamine (Table 3).
Figure 2 shows individual data points for docosahexaenoic
acid and 1-O-19-(Z)-octadecenyl,2-docosahexaenoyl-sn-glycero-3-
phosphoethanolamine in liver, along with correlation analyses
between liver docosahexaenoic/a-linolenic ratios and most recent
MMSE and global deterioration scale scores. The ratios were
positively correlated with MMSE scores (Pearson’s correlation
Figure 1. Overview of docosahexaenoic acid biosynthesis in
liver. Diet-derived a-linolenic acid (C18:3n-3) is transformed into
tetracosahexaenoic acid (C24:6n-3) by the sequential action of D
6 and
D
5 desaturases (encoded by the FADS2 and FADS1 genes, respectively)
and elongases (such as that encoded by the HELO1 gene) present in the
endoplasmatic reticulum. Tetracosahexaenoic acid is transported into
peroxisomes (shaded area), presumably by proteins encoded by the
ABCD1 or ABCD2 genes, and then converted into docosahexaenoic acid
(C22:6n-3) by sequential action of acyl coenzyme-A oxidase (encoded
by the ACOX1 gene), D-bifunctional protein (encoded by the HSD17B4
gene), and various peroxisomal thiolases (not shown). The figure shows
chemical structures of fatty acids quantified in our analyses.
doi:10.1371/journal.pone.0012538.g001
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with global deterioration scale grades (P=0.013; Fig. 2D).
No differences were noted for free eicosatrienoic acid and
arachidonic acid. In nanomoles per gram of tissue, eicosatrienoic
acid was 75.26633.37 in control subjects and 88.80639.40 in
Alzheimer’s disease patients (P=0.17); and arachidonic acid was
522.466177.19 in control subjects and 435.966172.80 in
Alzheimer’s disease patients (P=0.46). A significant difference
was observed, however, for free linoleic acid, the content of which
was, in nanomoles per gram of tissue, 849.006277.48 in control
subjects and 580.176253.79 in Alzheimer’s disease patients
(P=0.042).
Docosahexaenoic acid biosynthesis in liver
The expression of genes involved in docosahexaenoic acid
biosynthesis was measured in the same liver samples. There were
statistically detectable differences only for the peroxisomal enzyme
D-bifunctional protein (encoded by the HSD17B4 gene), which
Table 1. Levels of free docosahexaenoic acid (nmol/g) and docosahexaenoate-containing phosphatidylethanolamine (nmol/g) in
various brain regions of control subjects and subjects with Alzheimer’s disease.
Control subjects Subjects with Alzheimer’s disease Adjusted Difference P-value
*
Mean ± SD ; N Mean ± SD ; N (95% CI)
DHA
Temporal cortex 123.61624.07 ; 17 102.29640.66 ; 36 223.87 ( 245.18, 22.57 ) 0.029
Frontal cortex 119.99650.8 ; 17 97.45626.19 ; 37 222.11 ( 242.37, 21.85 ) 0.033
Cerebellum 218.186101.66 ; 16 174.86645.22 ; 35 242.58 ( 283.31, 21.84 ) 0.041
Pooled 152.64679.12 ; 17 124.35651.72 ; 37 228.87 ( 249.81, 27.94 ) 0.007
Phosphatidylethanolamine
**
Temporal cortex 11.5263.58 ; 17 8.2664.06 ; 36 23.22 ( 25.56, 20.88 ) 0.008
Frontal cortex 29.765.94 ; 17 23.8365.84 ; 37 25.82 ( 29.32, 22.32 ) 0.002
Cerebellum 13.7164.16 ; 16 10.3764.75 ; 35 23.44 ( 26.28, 20.61 ) 0.018
Pooled 18.469.43 ; 17 14.3268.6 ; 38 24.14 ( 27.2, 21.09 ) 0.008
Abbreviations: CI, confidence interval.
*P-values for differences between means were computed by linear regression analysis for each fatty acid in selected brain regions and Generalized Estimating Equations
for the pooled analysis in the entire brain after adjustment for age, gender, and post mortem interval.
**Phosphatidylethanolamine was 1-stearoyl, 2-docosahexaenoyl-sn-glycero-phosphoethanolamine.
doi:10.1371/journal.pone.0012538.t001
Table 2. Levels of free n-3 fatty acids (nmol/g) in various brain regions of control subjects and subjects with Alzheimer’s disease.
n-3 Fatty acid Control subjects
Subjects with
Alzheimer’s disease Adjusted Difference P-value
*
Mean ± SD ; N Mean ± SD ; N (95% CI)
a-Linolenic (C18:3)
Temporal cortex 1.7560.36 ; 17 1.9560.76 ; 36 0.17 ( 20.22, 0.57 ) 0.387
Frontal cortex 2.0760.42 ; 17 2.4660.79 ; 37 0.39 ( 0.01, 0.78 ) 0.045
Cerebellum 1.6560.54 ; 16 1.9160.59 ; 35 0.27 ( 20.08, 0.62 ) 0.130
Pooled 1.8260.47 ; 17 2.1260.76 ; 37 0.29 ( 0.06, 0.52 ) 0.019
Eicosapentaenoic (C20:5)
Temporal cortex 2.1361.18 ; 17 1.9561.34 ; 36 20.21 ( 20.99, 0.58 ) 0.596
Frontal cortex 2.1861.09 ; 17 2.2761.57 ; 37 0.08 ( 20.8, 0.97 ) 0.848
Cerebellum 1.6461.11 ; 16 1.4660.48 ; 35 20.17 ( 20.62, 0.27 ) 0.437
Pooled 1.9961.13 ; 17 1.961.26 ; 37 20.06 ( 20.59, 0.47 ) 0.829
Docosapentaenoic (C22:5)
Temporal cortex 3.9862.52 ; 17 3.7263.23 ; 36 20.24 ( 22.09, 1.61 ) 0.718
Frontal cortex 7.4561.69 ; 17 7.2562.41 ; 37 20.15 ( 21.45, 1.16 ) 0.821
Cerebellum 9.4564.59 ; 16 9.6762.78 ; 35 0.20 ( 21.87, 2.26 ) 0.850
Pooled 7.0163.81 ; 17 6.8463.72 ; 37 20.17 ( 21.28, 0.94 ) 0.919
Abbreviations: CI, confidence interval.
*P-values for differences between means were computed by linear regression analysis for each fatty acid in selected brain regions and Generalized Estimating Equations
for the pooled analysis in the entire brain after adjustment for age, gender, and post mortem interval.
doi:10.1371/journal.pone.0012538.t002
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hexaenoic acid [17,18] (Table 4). Individual data points for
HSD17B4 mRNA are reported in Figure 2E.
Since D-bifunctional protein participates in the degradation of
branched-chain fatty acids, such as phytanic acid and pristanic
acid, the levels of these compounds were also measured. In
nanomoles per gram of tissue, phytanic acid was 1.9360.51 in
control subjects and 4.3361.80 in Alzheimer’s disease patients
[adjusted difference (95% confidence intervals): 2.53 (1.17, 3.90);
P=0.001]; pristanic acid was 2.1061.05 in control subjects and
4.2361.58 in Alzheimer’s disease patients [adjusted difference
(95% confidence intervals): 2.37 (1.03, 3.70); P=0.002]. Individ-
ual data points for pristanic acid are shown in Figure 2F.
Discussion
The first objective of this study was to reexamine the association,
suggested by past reports [6,24–30], between Alzheimer’s disease
and lowered brain docosahexaenoic acid content. Our findings
provide new evidence in support of such association and further
reveal the existence of a positive correlation between brain
docosahexaenoic acid levels and cognitive status. To identify
potential mechanisms responsible for the observed breakdown in
brain docosahexaenoic acid integrity, we next focused our attention
on the liver because of the critical role played by this organ in
supplying docosahexaenoic acid to the brain [5,9,13]. Our results
indicate that docosahexaenoic acid levels and expression of D-
bifunctional protein, a key enzyme of docosahexaenoic acid
biosynthesis, are selectively reduced in liver of Alzheimer’s disease
patients. The functional significance of these findings is underscored
by the identification of a strong positive correlation between liver
docosahexaenoic acid content and cognitive status (P,0.0001).
Previous studies have suggested that brain levels of docosahex-
aenoic acid [6] and docosahexaenoic acid-containing phospholip-
ids [24–30] are reduced in Alzheimer’s disease (see [31] for a
discussion of discordances). Our investigations confirmed those
results. In agreement with Lukiw et al. (2005) [6], we found that
docosahexaenoic acid is reduced in temporal cortex and mid-
frontal cortex from 37 subjects with Alzheimer’s disease, compared
to 17 closely matched control subjects. Additionally, our analyses
suggested that (i) this deficit is selective for docosahexaenoic acid,
because other n-3 or n-6 fatty acids are only marginally affected,
and (ii) docosahexaenoic acid levels in temporal cortex and mid-
frontal cortex positively correlate with cognitive status. This
correlation highlights the significance of brain docosahexaenoic
acid in normal cognition, though further research is needed to
determine if it represents cause and effect.
We were surprised to find that a decrease in docosahexaenoic
acid was clearly detectable in cerebellum, a brain region that is
regarded as being less vulnerable to Alzheimer’s pathology. This
finding led us to hypothesize that the alteration in brain
docosahexaenoic acid might result from a systemic deficiency in
the biosynthesis of this fatty acid. In mammals, the enzyme
pathway responsible for docosahexaenoic acid production is
primarily localized to the liver [5,9,13]. Therefore, to determine
whether this pathway is dysfunctional in Alzheimer’s disease, we
examined the lipid composition of liver samples from 14 patients
and 9 control subjects, who displayed no histological sign of liver
pathology. Our analyses show that liver tissue from Alzheimer’s
patients contains reduced levels of docosahexaenoic acid, but
elevated levels of tetracosahexaenoic acid and other n-3 fatty acids.
This profile is incompatible with a nutritional deficit in n-3
fatty acids and is suggestive of a defect in the last step of
docosahexaenoic acid biosynthesis – the b-oxidative conversion of
tetracosahexaenoic acid into docosahexaenoic acid, which occurs
in liver peroxisomes (Fig. 1). Two additional findings support this
interpretation and point to a selective involvement of peroxisomal
D-bifunctional protein: the accumulation of pristanic acid and
phytanic acid, two substrates for liver D-bifunctional protein, and
the lowered expression of the HSD17B4 gene, which encodes for
this protein [17,18,33]. Notably, other genes included in our panel
were not significantly different between Alzheimer’s disease
patients and control subjects. These results are consistent with
previous reports suggesting that D-bifunctional protein mutations
are associated with reduced docosahexaenoic acid levels in human
liver and brain [34,35].
The pathological events that lead to down-regulation of liver D-
bifunctional protein in Alzheimer’s disease remain to be
discovered. However, a role for oxidative stress, which is known
to accelerate age-dependent liver peroxisomal damage [36–38],
might be hypothesized. Furthermore, it is important to note that
our analyses were focused on docosahexaenoic acid biosynthesis
and did not evaluate the potential impact of other aspects of
docosahexaenoic acid metabolism – including transport and
oxidation.
A significant outcome of our analyses was the discovery that
liver docosahexaenoic acid levels are positive correlated with
MMSE scores, and negatively correlated with global deterioration
Table 3. Levels of free n-3 fatty acids (nmol/g) and docosahexanoate-containing phosphatidylethanolamine (nmol/g) in liver of
control subjects and subjects with Alzheimer’s disease.
n-3 Fatty acid Control subjects
Subjects with
Alzheimer’s disease Adjusted Difference P-value
*
Mean ± SD ; N=9 Mean ± SD ; N=14 (95% CI)
a-Linolenic (C18:3) 28.5567.88 36.72622.05 11.19 (24.53, 26.9) 0.152
Eicosapentaenoic (C20:5) 44.57614.74 67.4629.46 27.29 (6.69, 47.88) 0.012
Docosapentaenoic (C22:5) 21.5168.97 32.39613.82 12.7 (2.37, 23.03) 0.019
Tetrahexaenoic (C24:6) 0.7360.17 0.960.21 0.19 (0.01, 0.38) 0.041
Docosahexaenoic (C22:6) 324.836122.89 204.64674.62 2107.79 (2187.71, 227.87) 0.011
Phosphatidylethanolamine
** 75.49632.30 46.42615.73 234.68 (255.86, 213.50) 0.003
Abbreviations: CI, confidence interval.
*P-values for differences between means were computed by linear regression analysis after adjustment for age, gender, and post mortem interval.
**Phosphatidylethanolamine was 1-O-19-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine.
doi:10.1371/journal.pone.0012538.t003
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12538Figure 2. Liver metabolism in Alzheimer’s disease patients. Levels of free docosahexaenoic acid (Panel A) and 1-O-19-(Z)-octadecenyl, 2-
docosahexaenoyl-sn-glycero-3-phosphoethanolamine (Panel B) in liver tissue from control subjects (open squares) and Alzheimer’s disease patients
(closed circles). Correlation between individual docosahexaenoic/a-linolenic ratios in liver and most recent Mini-Mental State Examination scores
(Panel C) or global deterioration scale grades (Panel D). HSD17B4 mRNA, encoding for D-bifunctional protein (Panel E) and pristanic acid levels (Panel
F) in liver from control subjects (open squares) and subjects with Alzheimer’s disease (closed circles). Lipid content is expressed in nanomoles per
gram of wet tissue and mRNA levels are expressed in arbitrary units. There were statistically detectable differences between control subjects and
Alzheimer’s disease patients in the levels of docosahexaenoic acid (P=0.0077) and 1-O-19-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-
phosphoethanolamine (P=0.003) by two-tailed Welch’s t-test. There was a significant correlation between docosahexaenoic/a-linolenic ratios in liver
and Mini-Mental State Examination scores with use of the partial correlation analysis after adjustment for age, gender and post mortem interval.
Global deterioration scale grades correlate significantly (P=0.013) with the docosahexaenoic/a-linolenic ratios using a linear regression analysis
adjusting for age, gender and post mortem interval. There were statistically detectable differences between control subjects and patients in the levels
of HSD17B4 mRNA (P=0.048) and pristanic acid (P=0.0009) by two-tailed Welch’s t-test.
doi:10.1371/journal.pone.0012538.g002
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advanced liver diseases show a decline in cognitive abilities [39],
these findings reveal a previously unrecognized association
between hepatic docosahexaenoic acid homeostasis and global
cognition, and suggest that subtle changes in liver docosahex-
aenoic acid metabolism might be associated with dementia. This
supports early suggestions that in neurodegenerative disorders and
aging, a failure in the supply of docosahexaenoic acid from the
liver may take place [9]. Moreover, a circulatory ‘‘long loop’’
connects the supply of docosahexaenoic acid to the biogenesis of
excitable and photoreceptor membranes [40]. In retinal degener-
ative diseases, a shortage of blood docosahexaenoic acid has been
demonstrated, and a failure of the ‘‘long loop’’ from the liver is
suggested to underlie these changes [41]. Future prospective
investigations should explore the temporal relationship between
such changes and the development of Alzheimer’s pathology. As
with all observational studies, there is the possibility that
unmeasured factors may explain our results, even though we
chose a priori to adjust for the three most likely confounders – age,
gender and post mortem interval. Furthermore, though limited by
the lack of information on dosages and treatment duration, our
analysis of the medication record reveals no obvious correlation
between individual drug classes and liver docosahexaenoic acid
(Figure S2). Despite these inevitable limitations, our results do
suggest that a dysfunction in liver docosahexaenoic acid
metabolism, at least partly caused by abnormal D-bifunctional
protein expression, might predispose persons to Alzheimer’s
disease. This has implications both for clinical interventions with
n-3 fatty acids, which should take into consideration the limited
ability of Alzheimer’s disease patients to complete docosahexae-
noic acid biosynthesis, and for the discovery of peripheral lipid
biomarkers of Alzheimer’s disease.
Materials and Methods
Study design and tissue procurement
We conducted this study in two parts. We first determined
whether brain levels of docosahexaenoic acid are altered in
Alzheimer’s disease [6,24–30] and whether such alterations
correlate with cognitive status. We used frozen brain samples
from a total of 17 non-demented control subjects and 37
pathologically confirmed subjects with Alzheimer’s disease
(males/females: control subjects, 10/7; subjects with Alzheimer’s
disease, 20/17), provided by the Institute for Brain Aging and the
Dementia and Alzheimer’s Disease Research Center at the
University of California, Irvine. Three brain areas were selected
for analysis: temporal cortex (Broadmann area 20; 17 control
subjects and 36 subjects with Alzheimer’s disease), mid-frontal
cortex (Broadmann area 9; 17 control subjects and 37 subjects
with Alzheimer’s disease), and cerebellum (16 control subjects and
35 subjects with Alzheimer’s disease). Subjects were matched for
age (in years: control subjects, 80.568.5; subjects with Alzheimer’s
disease, 80.567.3) and post mortem interval (in hours: control
subjects, 4.461.5; subjects with Alzheimer’s disease, 4.261.7).
Alzheimer’s disease cases met the National Institute on Aging-
Reagan Institute criteria for intermediate or high likehood of
Alzheimer’s disease. Mini Mental State Examination (MMSE)
scores, a measure of cognitive status, were available for 10 control
subjects (mean score6SD=28.361.8; assessed 44.3635.9 months
before death) and 29 subjects with Alzheimer’s disease (mean
score6SD=12.467.2; assessed 11.066.2 months before death).
Because the liver is a primary source of brain docosahexaenoic
acid, in the second part of the study we examined whether
Alzheimer’s disease might be associated with alterations in liver n-
3 fatty acid metabolism. Frozen liver samples from a separate
cohort of 9 control subjects and 14 subjects with Alzheimer’s
disease (males/females: control subjects, 7/2; subjects with
Alzheimer’s disease, 8/6) were obtained from the Banner Sun
Health Research Institute (Sun City, AZ). These were selected
from a larger available pool because they were negative for
hepatitis B or hepatitis C antibodies and, at autopsy, revealed no
histological signs of liver disease (by hematoxylin/eosin staining).
They were matched for age (in years: control subjects, 83.965.4;
subjects with Alzheimer’s disease, 84.666.7) and post mortem
interval (in hours: control subjects, 3.460.9; subjects with
Alzheimer’s disease, 3.260.6). Alzheimer’s disease cases met the
National Institute on Aging-Reagan Institute criteria for interme-
diate or high likelihood of Alzheimer’s disease. MMSE scores were
available for 7 control subjects (mean6SD=28.161.7; assessed
7.165.6 months before death) and 12 subjects with Alzheimer’s
Table 4. Expression of genes involved in docosahexaenoic acid biosynthesis and peroxisomal function in liver of control subjects
and subjects with AD.
Gene Control Subjects Subjects with Alzheimer’s disease Adjusted Difference P-value
*
Symbol Mean ± SD; N=9 Mean ± SD; N=14 (95% CI)
FADS2 0.0260.029 0.01660.0099 20.0017 (20.02, 0.017) 0.851
HELO1 0.01160.012 0.00660.0046 20.0043 (20.012, 0.0036) 0.265
FADS1 0.03760.061 0.02460.026 20.0071 (20.044, 0.03) 0.693
ABCD1 0.02760.034 0.0260.024 20.0089 (20.036, 0.018) 0.500
ABCD2 8e-0460.001 0.001160.0013 0.00031 (28e-04, 0.0014) 0.567
ACOX1 0.260.24 0.3160.68 0.069 (20.45, 0.59) 0.782
HSD17B4 0.1860.045 0.1460.046 20.041 (20.083, 20.00039) 0.048
PEX13 0.04160.017 0.03760.017 20.0047 (20.022, 0.012) 0.569
PEX14 0.008760.004 0.01360.022 0.0029 (20.013, 0.019) 0.700
PEX19 0.01860.018 0.01260.0054 20.0055 (20.016, 0.0051) 0.291
Abbreviations: CI, confidence interval.
*P-values for differences between means were computed by linear regression analysis after adjustment for age, gender, and RNA integrity number.
Hydroxysteroid (17-beta) dehydrogenase 4, HSD17B4; for other abbreviations see Text S1.
doi:10.1371/journal.pone.0012538.t004
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fore death). Global deterioration scale scores were available for 6
control subjects and 9 subjects with Alzheimer’s disease.
All subjects and their caregivers (when appropriate) provided
written informed consent for both the clinical examination as well
as for brain donation at the University of California Irvine and for
liver donation at the Banner Sun Health Research Institute Brain
and Body Donation Program. The protocols and informed
consent have been approved by the University of California
Irvine Institutional Biosafety Committee and the Banner Health
Institutional Review Board.
Lipid and gene expression analyses
Analyses are described in Text S1 available online with this
article.
Statistical analyses
Descriptive statistics are presented as means 6 SD. The
differences between unadjusted mean values were determined by
two-tailed Welch’s t-test. Associations between parameters were
tested by partial correlation analysis (Pearson’s). Generalized
Estimating Equations [42] were used to determine the overall
association of individual lipid species with Alzheimer’s disease –
adjusting for the a priori-specified potential confounders of age,
gender, and post mortem interval – by pooling data across frontal
cortex, temporal cortex and cerebellum. An exchangeable working
correlation structure was used in model fitting, and robust
standard errors [43] were used for inference in the Generalized
Estimating Equations analysis. Adjusting for the covariates listed
above, we used linear regression to estimate the association
between individual lipid species and Alzheimer’s disease. Linear
regression was also utilized to determine differences in mRNA
expression levels adjusting for age, gender, and RNA integrity
number. All confidence intervals correspond to a 95% confidence
level without adjustment for multiple comparisons.
Supporting Information
Text S1 Supplementary Materials and Methods.
Found at: doi:10.1371/journal.pone.0012538.s001 (0.06 MB
DOC)
Figure S1 Levels of free DHA (Panel A) and 1-stearoyl-2-
docosahexaenoyl-sn-glycero-3-phosphoethanolamine (Panel B) in
temporal cortex of control subjects (open squares) and subjects
with AD (closed circles). Correlation analysis between individual
docosahexaenoic/a-linolenic ratios in temporal cortex and most
recent Mini-Mental State Examination scores (Panel C). Lipid
content is expressed in nanomoles per gram of wet tissue. There
were statistically detectable differences between control subjects
and patients in the levels of DHA (P=0.019) and 1-stearoyl-2-
docosahexaenoyl-sn-glycero-3-phosphoethanolamine (P=0.0084)
by two-tailed Welch’s t-test. There was a significant correlation
between docosahexaenoic/a-linolenic ratios and Mini-Mental
State Examination scores by partial correlation analysis after
adjustment for age, gender and post mortem interval.
Found at: doi:10.1371/journal.pone.0012538.s002 (6.78 MB TIF)
Figure S2 Correlation between liver docosahexaenoic acid and
individual drug classes taken by the control subjects (open squares)
and Alzheimer’s disease patients (closed circles).
Found at: doi:10.1371/journal.pone.0012538.s003 (6.78 MB TIF)
Table S1 Levels of free n-6 fatty acids (nmol/g) in various brain
regions of control subjects and subjects with Alzheimer’s disease.
Found at: doi:10.1371/journal.pone.0012538.s004 (0.10 MB
DOCX)
Table S2 List of medications taken by the subjects involved in
the liver study.
Found at: doi:10.1371/journal.pone.0012538.s005 (0.06 MB
DOCX)
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